LakeShore Biopharma Co., Ltd (LSBCF)

Market Cap	31.73M
Revenue (ttm)	84.75M
Net Income (ttm)	-13.78M
Shares Out	41.21M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,215
Average Volume	37,686
Open	0.7701
Previous Close	0.7801
Day's Range	0.7700 - 0.7851
52-Week Range	0.3001 - 3.9900
Beta	0.56
RSI	49.31
Earnings Date	n/a

About LakeShore Biopharma

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 573
• Stock Exchange: OTCMKTS
• Ticker Symbol: LSBCF

Financial Performance

In 2024, LakeShore Biopharma's revenue was 614.96 million, an increase of 7.24% compared to the previous year's 573.42 million. Losses were -99.98 million, -76.93% less than in 2023.

Financial numbers in CNY